Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Prediction
Cronos (cron) will do an equity financing with Hill Street Beverages, giving them at least a 49% interest and a DehydraTech license in Canada. Then in order to acquire the exclusive US rights to Lexaria's DehydraTECH for use with CBD/THC either Cronos or Altria will take an equity interest in Lexaria Hemp (45%) with the option to purchase 100% in the future based on value.
The meeting materials for Cronos Group Inc.'s special meeting of holders of common shares to be held on Feb. 21, 2019, including the management proxy circular dated Dec. 31, 2018, prepared in connection with the proposed $2.4-billion equity investment by Altria Group Inc.
Thanks for joining in. I for one will be interested in your opinion of Lexaria DehydraTECH once you have completed your DD. You might also try phoning Mr. John Docherty at Lexaria.
Go to the US patent office and search for Lexaria's patents. That will probably be your best explanation of their technology.
"...an exclusive basis in the United States and a non-exclusive basis elsewhere globally."
So Altria now controls a LP. Altria has their own vaporization tech that they can use for the delivery of cannabis but they lack a delivery technology for drinks and edibles. Let me think, who could help them out here? I know Lexaria Hemp!
"Lexaria Hemp Corp., a US company globally licensed to provide DehydraTECH to the rapidly growing hemp-based foods and supplements industries. Lexaria Hemp Corp. is currently involved in discussions with a number of companies regarding the utilization of its technology in CBD-from-hemp products for the Canadian and US markets following recent announcements of regulatory advancement in both countries. Discussions with companies in other global markets are also underway with reportable progress expected soon."
https://www.forbes.com/sites/greatspeculations/2018/12/26/cronos-group-benefits-from-the-altria-deal-in-multiple-ways/#2c2ded993648
And another 1 million shares traded in The Great White North!
Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive investment agreement.
- The Altria investment will fund research on regulatory compliant, oral forms of nicotine delivery.
- Altria has been granted exclusive DehydraTECH (TM) license rights to commercialize oral nicotine products in the United States.
- Lexaria Bioscience retains majority equity ownership of Lexaria Nicotine LLC.
Kelowna, British Columbia / TheNewswire / January 15, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) ( "Lexaria Bioscience"), a drug delivery platform innovator, is pleased to announce that its wholly-owned subsidiary Lexaria Nicotine LLC ("Lexaria Nicotine") and Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc. (NYSE:MO) ("Altria"), have executed definitive agreements to pursue innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECH (TM) technology. Lexaria's DehydraTECH(TM) technology enhances the performance of beneficial compounds in ingestible products across four categories: taste & smell, speed of action, bio-absorption and bioavailability.
Funding
Altria is funding a milestone-based research & development program ("R&D Program") in exchange for a minority equity interest in Lexaria Nicotine and certain DehydraTECH(TM) license rights. Altria will provide initial funding of US$1 million, with the option for additional funding of up to US$12 million through multiple phased private financings.
R&D Program
Lexaria Nicotine will execute a comprehensive series of clinical investigations of oral forms of nicotine delivery, utilizing Lexaria's patented DehydraTECH TM technology.
DehydraTECH (TM) License
Altria has been granted a license to use Lexaria Bioscience's patented DehydraTECH (TM) technology for oral nicotine delivery forms on an exclusive basis in the United States and a non-exclusive basis elsewhere globally. Altria will pay Lexaria Nicotine a royalty on revenue generated from the sale of nicotine products containing DehydraTECH(TM), until such time it may acquire 100% ownership in Lexaria Nicotine.
Additional Information
Altria will initially have the right to appoint one of the seven directors on Lexaria Nicotine's board of directors and, through the additional phased investments, may have the right to appoint up to three of the seven directors.
Altria has the option to acquire 100% ownership interest in Lexaria Nicotine commensurate with then-current fair market value. Lexaria Bioscience has not sold or optioned any of its own equity. As announced on October 10, 2018, Lexaria Bioscience has created a number of individual subsidiaries - including Lexaria Nicotine - in a structure whereby Lexaria Bioscience retains ownership of its patented DehydraTECH (TM) technology and licenses its use to multiple molecular classes, including nicotine.
Management Commentary
"Lexaria Bioscience is proud that, after careful selection, Altria has chosen to fund research into DehydraTECH(TM) technology and potentially commercialize this technology for oral nicotine," remarks Chris Bunka, CEO of Lexaria Bioscience. "This partnership will provide significant benefits to Lexaria Bioscience and its shareholders with a world-class R&D Program and regulatory compliance process. We believe Altria is the best corporate partner we could work with to truly make a difference in the lives of millions of consumers."
"Lexaria Bioscience has repeatedly demonstrated the powerful effects of its patented DehydraTECH (TM) technology for enhancing the palatability and speed of onset of orally-consumed bioactive substances such as nicotine," added John Docherty, President of Lexaria Bioscience. "Laboratory research to date on oral nicotine formulations has been quite encouraging. We are very excited to advance the clinical phases of our comprehensive R&D Program together with Altria with a view to full commercial product development."
Advisors
Borden Ladner Gervais LLP acted as independent legal counsel to Lexaria Bioscience and Lexaria Nicotine. Hunton Andrews Kurth LLP acted as independent legal counsel to Altria.
About Lexaria Bioscience
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has ten patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria's technology provides more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
Lexaria Nicotine LLC is a United States domiciled, majority-owned subsidiary of Lexaria Bioscience Corp., focused on reduced-risk nicotine solutions.
www.lexarianicotineco.com
For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp
and on Facebook https://www.facebook.com/lexariabioscience/
About Altria Group
Altria's wholly-owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria holds an equity investment in Anheuser-Busch InBev SA/NV (AB InBev).
The brand portfolios of Altria's tobacco operating companies include Marlboro (R) , Black & Mild (R) , Copenhagen (R) and Skoal (R) . Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle (R) , Columbia Crest (R) , 14 Hands (R) and Stag's Leap Wine Cellars (TM) , and it imports and markets Antinori (R) , Champagne Nicolas Feuillatte (TM) , Torres (R) and Villa Maria Estate (TM) products in the United States. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission. More information about Altria is available at altria.com and on the Altria Investor app.
Take a closer look at Altria and its companies on altria.com.
Follow Altria on Twitter at @AltriaNews.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. Lexaria Bioscience makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that the R&D Program will be successful or result in any regulator-approved products or that the contemplated royalties will generate material revenue. Such forward-looking statements are estimates reflecting Lexaria Bioscience's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by Lexaria Bioscience include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in Lexaria Bioscience's public announcements and filings. There is no assurance that existing capital is sufficient for Lexaria Bioscience's needs or that it will be able to raise additional capital. There is no assurance that Lexaria Bioscience will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact as can any results that cannot be reproduced in subsequent testing. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria Bioscience's postulated uses, benefits, or advantages for the patented and patented technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). DehydraTECH TM technology is not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Copyright (c) 2019 TheNewswire - All rights reserved.
© 2019 Canjex Publishing Ltd. All rights reserved.
What a joke, American Premium has a market cap of $1,248,000. This article was a paid article to try and lump American Premium in with the big legitimate players methinks.
This is interesting because Growpacker had originally signed a licensing deal with Lexaria, a deal that was ultimately canceled and now they've signed with someone else.
"American Premium Water Corporation, a company with one foot already in the growing CBD beverage market with its LALPINA Hydro CBD water, announced in October that it developed a formulation using its proprietary Hydro-Nano technology for THC. In December it announced they had entered into an agreement with Growpacker, a California based company that does infusion and fulfilment in the CBD and cannabis sector. Growpacker has a number of relationships with dispensaries in the state, and provides the distribution network for the Company to sell into the US’s largest marijuana market."
Breaking News: The Multi-Billion Dollar US and Canadian CBD-Infused Beverage Race is On: Tilray, Coca Cola, Molson Coors Brewing Co., Heineken and American Premium Water Corporation on Watch
2019-01-14 10:30 ET - News Release
NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- OTCMarketsinsider.com News Commentary
2019 is poised to be a pivotal year for the cannabis-infused-beverage market. Investors seeking to profit from the early growth of this new opportunity have plenty of options to choose from.
Canaccord’s Bobby Burleson and Jonathan DeCourcey claimed that infused beverages could be poised to outpace general demand for marijuana products by two fold, taking 20% of the existing market for cannabis edibles by 2022.
Canadian cannabis company Tilray entered a $100 million joint venture with beer brewer AB InBev to study cannabis-based beverages. The joint venture, in which both companies will invest $50 million, will study non-alcoholic beverages containing THC, the psychoactive chemical compound in marijuana, as well as CBD, the non-active chemical.
Heineken also launched a JV in California's, the world's biggest marijuana market. In June 2018, Heineken subsidiary Lagunitas announced a partnership with cannabis company AbsoluteXtracts to market cannabis-infused sparkling water products under the brand name Hi-Fi Hops. The products became available to consumers in July 2018. One version of Hi-Fi Hops contains 10 mg of THC, while the other contains 5 mg of THC and 5 mg of CBD.
Coca-Cola Co. said it’s eyeing to enter the CBD market, becoming the latest beverage company to tap into surging demand for marijuana products as traditional sales slow. Coca-Cola says it’s monitoring the nascent industry and is interested in drinks infused with CBD.
Last August, Molson Coors entered into a joint venture with HEXO, a Quebec-based marijuana cultivator, to produce cannabis-infused beverages for the Canadian market. Canada legalized marijuana for all adults on October 17, though products like beverages, edibles, and vaporizers won't be available until the fall of 2019.
The CEO of Molson Coors is bullish on cannabis-infused beverages. During the company's third-quarter earnings call, CEO Mark Hunter said the cannabis market could total $7 billion to $10 billion in Canada alone. Nonalcoholic cannabis-infused beverages could account for as much as $3 billion, or 30% of the total market.
Mark Hunter said Molson Coors, through the joint venture, was "well-placed" to take a meaningful share of that market when it opens up. "We decided as a business that we did not want to be a spectator as this new market opened up," Hunter said. "And we clearly wanted to be a participant."
American Premium Water Corporation, a company with one foot already in the growing CBD beverage market with its LALPINA Hydro CBD water, announced in October that it developed a formulation using its proprietary Hydro-Nano technology for THC. In December it announced they had entered into an agreement with Growpacker, a California based company that does infusion and fulfilment in the CBD and cannabis sector. Growpacker has a number of relationships with dispensaries in the state, and provides the distribution network for the Company to sell into the US’s largest marijuana market.
For commentary inquiries, please contact: info@otcinsider.com
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CG undertakes no obligation to update such statements.
You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. OTCI was not compensated by, (OTC: HEINY), (NASDAQ:TLRY), (NYSE: TAP), (OTC: HIPH) or any other company mentioned in this article.
Full Disclaimer: http://www.otcinsider.com/disclaimer/
For commentary inquiries, please contact: info@otcinsider.com
Biolog has licensed DehydraTECH from Lexaria and it seems Biolog is selling products made using LXRP's tech to WCVC.
DehydraTECH uses only GRAS (generally recognized as safe) ingredients
This is important, a number of companies claim to be able to dissolve oils in liquid, but what chemical are they using as the emulsifier? Maltodextrin is being used by at least one company, yuk!
Very Low Nicotine Content Cigarettes
Nobodys going to buy this crap! They want nicotine, hello. If this is all that's left on the market then Vapes and LXRP's product will be in high demand. It's like saying, " fine you can smoke weed recreationally but we're taking all the THC out of it.."
https://www.businesswire.com/news/home/20181227005331/en/
Wallstreet, you might want to type what you want to say in your native language and then use Google Translate to change it to English.
It's your mind they want!
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Increases
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Increases the Performance of Products for Third-Party Partners
- Changing the way cannabinoids and nicotine enter the blood stream
- Enhancing products worldwide, with patents issued and pending in more than 40 countries
- Providing a powerful new delivery method with a cost of less than a penny per serving to implement
Smoking is an efficient way to absorb cannabis and nicotine into the blood stream. However, it is also a health hazard that takes the lives of over six million people each year through smoking-related diseases.
What would it mean for the cannabis, nicotine and other medicinal industries if the dangers of lighting up were eliminated from the equation? What if a more effective way of delivering drugs was developed that reduced quantity and increased effectiveness without the negative side effects? One company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), set out to answer these questions.
Lexaria’s revolutionary technology, DehydraTECH, changed the way that fat soluble, plant-derived molecules (such as cannabinoids and nicotine) enter the body.
The first challenge when creating edibles is taste and smell. Cannabinoids and nicotine can be bitter when taken orally. For this reason, edibles often contain high levels of sugar. DehydraTECH masks the taste and smell, eliminating the need for unhealthy sweeteners while making the product more desirable for the consumer.
Once past the mouth, these molecules do not fully survive the acidic nature of the stomach. Though the ideal location for absorption is in the small intestine, the stomach damages the molecules before they have a chance to arrive. DehydraTECH provides protection during stomach transit and can even bypasses first pass liver metabolism when desired. The truth is that the vast majority of substances orally consumed end up being filtered through the body as waste. With the addition of DehydraTECH, this changes! Bio absorption is increased by five to 10 times.
Four different wholly owned subsidiaries operate under Lexaria. Each is empowered with global exclusive licenses to use and out-license DehydraTECH to third party partners within their respective industries in more than 40 countries where the technology is patented or patent-pending. Partners are offered a competitive edge and protection against inferior methodologies and outdated technology. DehydraTECH is suitable for use in processed foods, beverages, capsules, oral sprays, topical applications and more. Though the company is doing extensive research and evaluating the potential use of its technology for nicotine delivery, it is not partnering with the tobacco industry.
Chemicals or intimidating complex ingredients that require disclosure on food labels are not required additions when using DehydraTECH. Instead the edible tech works with commons GRAS ingredients that can be organic and gluten- and dairy-free. It does all of this while still costing partners less than a penny per serving to implement, making DehydraTECH a win-win for the partner and consumer, who both gain from the improved performance of the enhanced product.
Lexaria believes that one day, using technologies like DehydraTECH, foods and beverages will be able to replace smoking as the most effective delivery mechanism. The work the company is doing with cannabinoids and nicotine is paving a path toward providing a powerful new delivery method of pain relievers, vitamins, supplements and more.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Instadose Pharma is owned by https://www.excellencehealthgroup.com/
Excellence not only sells bulk oils but also offers "Proprietary cannabis delivery systems to service both the medical and recreational markets including solubility and stability enhancement, modified release, and taste masking:"
As the cost of extracts falls the cost of infusion technologies becomes more and more critical. Those with the lowest cost per dose will win!
https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/canadas-largest-cannabis-producer-brings-down-cbd-oil-costs-by-96-34
Company: Lexaria Bioscience Corp. (LXRP)
Category: Stock Spotlights
December 26, 2018
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology company and drug delivery platform innovator, has submitted a Health Canada research application for a license to allow in-house research to be conducted at its Kelowna-based laboratory. A recent article further discussing the company reads, “Lexaria submitted its research application under Health Canada’s Cannabis Tracking and Licensing System for the operation of a research and development (R&D) laboratory to work with cannabinoids within the company’s new Kelowna head office, now under construction. In fact, Lexaria will commence experimental work on nicotine formulations, NSAIDs, vitamins and other bioactive compounds of interest after the completion of this laboratory facility. … The construction of the new head office and laboratory is advancing fast. Lexaria expects to occupy the new facility by the end of January 2019. The company is recruiting more staff to prepare for more wide-ranging operations. Moreover, Lexaria has taken delivery of specific equipment in a separate location where it is uniting known nano-emulsification processes with its DehydraTECH drug delivery platform for enhanced performance characteristics. This work will also transition to the Kelowna laboratory upon the facility being operational and licensed.”
To view the full article, visit http://nnw.fm/DHx91
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
More from NetworkNewsBreaks
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Appoints Chief Technology Officer Nitya G. Ray, Ph.D.
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Engages Counsel to Assist with Canadian Securities Exchange Dual Listing
NetworkNewsBreaks – Global Payout, Inc. (GOHE) Executes Licensing Agreement with GreenBox POS (GRBX)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
"Extracts can contain flavouring agents, but no sugars, sweeteners or sweetening agents."
This should also benefit LXRP. I wonder if Maltodextrin is classified as a sweetening agent, it is higher on the glycemic index than sugar.
Another company selling, liscening CBD powder. Like the other Pivot Pharma, Oleo is using Maltodextrin as the emulsifier. Using Maltodextrin takes their products out of the all-natural, healthy category. Maltodextrin has a higher glycemic index than sugar! Seems everyone who's using this powder is also mixing it with strong flavors, makes a kind of Freshi/Kool-aid like drink, not good for blood/sugar levels!
https://www.oleolife.com/
I managed to get one box of their tea shipped to me in Canada from the US, but by the time it got here with shipping, duty, GSTax and the exchange rate, that sucker cost me almost CDN $50.00. Cost is definitely prohibitive, but it is a really good quality tea.
Won't get any here in Canada as it's still technically illegal, can't get Turbo CBD either. Has anyone tried the Turbo CBD?
Well, that's all and good but John needs to be more of a talker as well as a doer!
This is one of the worst performing MJ stocks out there, and I along with other shareholders feel that we're being treated like mushrooms, kept in the dark and fed shit, it shouldn't be necessary for every shareholder to phone the company in an effort to find out what the hell is going on and what he's doing to turn this ship around!
Good communication is an important leadership skill!